09.05.25 -- STREAM Edition: Delivering Biologics To The Brain With Adaptin Bio's Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD

Learn how payloads and advanced payload intermediates can expedite drug development and elevate ADC therapies, and explore ADC payloads, payload intermediates, and solubility-enhancing technology.

In this presentation, experts provide insight into transposase-mediated genome engineering, genetic quality control, and the maintenance of genetic stability in cell line generation.

Science writer Thomas Levenson states that it is inherently difficult to identify current scientific and medical biases, drawing parallels to historical assumptions like miasma theory. He highlights that societal willingness dictates scientific research — for example, how political decisions in the US have shifted NIH and NSF focus from infectious diseases to chronic conditions.

Using a comprehensive approach to component selection mitigates risks to fill-finish and lyo processing. Explore key considerations for selecting lyophilization stoppers suitable for intended use.

In this episode of "Better Biopharma," host Tyler Menichiello is joined by Adaptin Bio's CEO, co-founder, and president, Michael Roberts, Ph.D., and Duke University's Mustafa Khasraw, MD to discuss Adaptin's Brain Bispecific T-cell Engager (BRiTE) platform.

Collaboration across sites is critical in the journey from development to manufacturing. Watch to discover how to accelerate cross-site collaboration with simple assay transfer.